Filing Flows › iSpecimen (ISPC) › Q1 2026
iSpecimen (ISPC) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 18, 2026
iSpecimen (ISPC) reported revenue of $156K for the first quarter 2026 (Q1 2026), -85% from a year earlier and +201% from the quarter before.
iSpecimen, Q1 2026: revenue $156K (-85% year over year), net loss $2.3M, operating cash flow −$3.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $156K | +201% | -85% |
| Operating profit | −$2.5M | — | — |
| Net earnings | −$2.3M | — | — |
| Operating cash flow | −$3.4M | — | — |
What changed
Revenue was $156K in Q1 2026, down 85% year over year and up 201% from the previous quarter. Product was the largest line at 86% of revenue. Product lost $843K year over year (down 86%), 93% of the total change.
Operating costs exceeded revenue by $2.5M, an operating margin of -1627.1%. Total costs fell 0% while revenue fell 85%. The fastest-growing cost line was Sales & marketing (+344%). The quarter ended with a net loss of $2.3M, narrower than the previous quarter's $5.0M loss.
Operating cash flow was −$3.4M. Non-cash charges added back $136K of depreciation and amortization and $1K of share-based compensation. Working capital and other items used $1.2M.
Questions
What was iSpecimen's revenue in the first quarter 2026?
iSpecimen (ISPC) reported revenue of $156K for the first quarter 2026 (Q1 2026), -85% from a year earlier and +201% from the quarter before.
Source: iSpecimen 10-Q on SEC EDGAR.